Free Trial

Roth Capital Has Bearish Estimate for biote FY2026 Earnings

biote logo with Medical background

Key Points

  • Roth Capital has revised biote Corp.'s FY2026 earnings per share estimate down to $0.44, significantly lower than the previous estimate of $0.70 and below the consensus estimate of $0.75.
  • biote reported earnings of $0.10 per share for the recent quarter, surpassing analyst expectations of $0.06, although revenue fell short at $48.86 million compared to estimates of $49.52 million.
  • Several research analysts have downgraded biote's stock rating, with B. Riley shifting from a "buy" to a "neutral" rating and lowering the price target from $8.00 to $4.00.
  • Want stock alerts on biote? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

biote Corp. (NASDAQ:BTMD - Free Report) - Equities researchers at Roth Capital cut their FY2026 earnings per share estimates for biote in a report issued on Thursday, August 7th. Roth Capital analyst G. Kelly now anticipates that the company will post earnings of $0.44 per share for the year, down from their prior estimate of $0.70. The consensus estimate for biote's current full-year earnings is $0.75 per share.

biote (NASDAQ:BTMD - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.04. The business had revenue of $48.86 million for the quarter, compared to analyst estimates of $49.52 million. biote had a negative return on equity of 19.71% and a net margin of 15.73%.

A number of other research analysts have also weighed in on BTMD. B. Riley lowered biote from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $8.00 to $4.00 in a report on Thursday. Wall Street Zen lowered biote from a "strong-buy" rating to a "hold" rating in a report on Saturday.

Get Our Latest Report on biote

biote Trading Down 1.4%

NASDAQ:BTMD opened at $2.88 on Monday. The firm has a market cap of $157.56 million, a P/E ratio of 3.20 and a beta of 1.21. The stock's 50 day simple moving average is $4.00 and its 200-day simple moving average is $4.01. biote has a 12-month low of $2.87 and a 12-month high of $6.98.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BTMD. CWM LLC grew its holdings in biote by 952.7% during the second quarter. CWM LLC now owns 8,674 shares of the company's stock worth $35,000 after acquiring an additional 7,850 shares during the period. Hsbc Holdings PLC purchased a new stake in biote during the first quarter worth $43,000. AQR Capital Management LLC purchased a new stake in biote during the first quarter worth $43,000. Virtu Financial LLC purchased a new stake in biote during the first quarter worth $62,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in biote during the second quarter worth $66,000. Institutional investors and hedge funds own 21.68% of the company's stock.

biote Company Profile

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

Featured Stories

Earnings History and Estimates for biote (NASDAQ:BTMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in biote Right Now?

Before you consider biote, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.

While biote currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines